Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 20 Fast-growings companies in PCSK9 Inhibitors
by Most Patent Filing In 5 Years in the world in 2022

The PCSK9 Inhibitors top 20 is Discovery PatSnap’ annual ranking of the top 20 Most Patent Filing In 5 Years PCSK9 Inhibitors Fast-growings in the world. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2022, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
The PCSK9 inhibitors are a class of injectable drugs approved in 2015 that have been shown to dramatically lower LDL cholesterol levels -- by up to 60% in some cases -- when combined with a statin.. PCSK9 inhibitors are monoclonal antibodies (MABs), a type of biologic drug. They bind to and inactivate an enzyme in the liver called proprotein convertase subtilisin kexin 9 (PCSK9).
#
Company Name
Region
Tech Topics
Total
1
Patent: 39
2
Hovedstaden, Denmark
Insulin,Health care,Haemophilia,
...[+2]
Patent: 28
3
Cambridgeshire, United Kingdom
Patent: 20
4
Cambridgeshire, United Kingdom
Medicine,Health care,Side effect,
...[+2]
Patent: 20
5
Basel-Stadt, Switzerland
Dosage form,Health care,Medicine,
...[+2]
Patent: 16
6
Health care,Biopharmaceutical,TUMOR NECROSIS FACTOR BLOCKER,
...[+2]
Patent: 6
7
Patent: 5
8
Health care,Mitral valve surgery,Health equity,
...[+2]
Patent: 5
9
Patent: 4
10
Dogma Therapeutics, Inc.
PCSK9,Cardiovascular agent,Biophysics,
...[+2]
Patent: 3
11
Patent: 3
12
Île-de-France, France
Patent: 3
13
Medicine,Health care,Drug class,
...[+2]
Patent: 3
14
Manchester, United Kingdom
Health care,Hospitality industry
Patent: 2
15
IF, FR
Patent: 2
16
South Korea
Patent: 2
17
Patent: 2
18
Patent: 2
19
Tokyo, Japan
Patent: 2
20
Patent: 2
Page generation time: May 17 2025